Patisiran inhibits TTR production in the liver, significantly decreasing neuropathy and stopping the advancement of the disease in patients with hATTR.569 Patisiran is known for its immense potential as an siRNA for treating brain diseases, and many siRNA therapies were later evaluated in late clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease (PD), and spinocerebellar ataxia. Here, TTR is linked to Alzheimer disease.